ROIVANT SCIENCES LTD
NASDAQ: ROIV (Roivant Sciences Ltd.)
Last update: 3 hours ago22.10
0.76 (3.56%)
| Previous Close | 21.34 |
| Open | 21.65 |
| Volume | 12,394,622 |
| Avg. Volume (3M) | 8,156,609 |
| Market Cap | 15,370,363,904 |
| Price / Sales | 694.83 |
| Price / Book | 3.23 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.60 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (HC Wainwright & Co., 17.65%) | Buy |
| 26.00 (Citigroup, 17.65%) | Buy | |
| Median | 21.50 (-2.72%) | |
| Low | 16.50 (B of A Securities, -25.34%) | Hold |
| Average | 21.94 (-0.72%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 16.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2025 | 26.00 (17.65%) | Buy | 22.10 |
| 18 Sep 2025 | 20.00 (-9.50%) | Buy | 15.09 | |
| Citigroup | 11 Nov 2025 | 26.00 (17.65%) | Buy | 20.90 |
| 29 Oct 2025 | 25.00 (13.12%) | Buy | 18.76 | |
| B of A Securities | 18 Sep 2025 | 16.50 (-25.34%) | Hold | 15.09 |
| Goldman Sachs | 18 Sep 2025 | 24.00 (8.60%) | Buy | 15.09 |
| Guggenheim | 18 Sep 2025 | 21.00 (-4.98%) | Buy | 15.09 |
| JP Morgan | 18 Sep 2025 | 20.00 (-9.50%) | Buy | 15.09 |
| Jefferies | 18 Sep 2025 | 20.00 (-9.50%) | Buy | 15.09 |
| Leerink Partners | 18 Sep 2025 | 22.00 (-0.45%) | Buy | 15.09 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 20.43 | -200,000 | -4,086,000 |
| Aggregate Net Quantity | -200,000 | |||
| Aggregate Net Value ($) | -4,086,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 20.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Officer | 09 Dec 2025 | Automatic sell (-) | 200,000 | 20.43 | 4,086,000 |
| VENKER ERIC | Officer | 09 Dec 2025 | Option execute | 200,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |